An interventional study of tubeless anesthesia and conventional intubation anesthesia in Tubeless Anesthesia, MWA (Microwave Ablation) and Ground-glass Nodules (GGNs), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by The First Affiliated Hospital of Guangzhou Medical University · Not applicable, Interventional, and Supportive care
Whether tubeless anesthesia provides clinically superior postoperative symptom recovery (measured by PSA-LUNG) and higher safety in patients undergoing VATS combined with microwave ablation (VATS+MWA)
This study is a multicenter, prospective, randomized controlled interventional clinical trial conducted by the Department of Thoracic Surgery at The First Affiliated Hospital of Guangzhou Medical University. The study primarily compares the efficacy and safety of tubeless anesthesia versus conventional endotracheal intubation anesthesia in video-assisted thoracoscopic surgery (VATS) combined with simultaneous microwave ablation (MWA) for the treatment of multiple high-risk pulmonary ground-glass nodules (GGNs), with the Postoperative Symptom Assessment scale for lung cancer surgery (PSA-LUNG)-a patient-reported outcome-as the core evaluation indicator.
A total of 80 patients with multiple high-risk GGNs who meet the inclusion criteria will be randomly assigned in a 1:1 ratio to two groups: the experimental group will undergo VATS combined with MWA under tubeless anesthesia, while the control group will undergo VATS combined with MWA under conventional intubation anesthesia. By assessing the PSA-LUNG score, technical success rate, perioperative complication rate, and postoperative changes in lung function, this study aims to determine whether tubeless anesthesia can provide patients with better postoperative symptom recovery and higher safety. Meanwhile, the dynamic changes in tumor markers will be explored to provide clinical evidence for optimizing perioperative anesthesia strategies in this patient population.
The First Affiliated Hospital of Guangzhou Medical University is the lead sponsor of 167 studies on the registry; 69 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
conventional intubation anesthesia
Procedure: conventional intubation anesthesia
tubeless anesthesia
Procedure: tubeless anesthesia
Tubeless (non-intubated) anesthesia: general anesthesia is induced and maintained without endotracheal intubation. The patient breathes spontaneously throughout the procedure. Anesthesia is maintained with intravenous agents (e.g., propofol, remifentanil) combined with regional anesthesia (thoracic paravertebral block or erector spinae plane block) and/or moderate sedation.
Also known as: Tubeless
Conventional intubation anesthesia: general anesthesia is induced with endotracheal intubation and the patient is mechanically ventilated throughout the procedure. Anesthesia is maintained with intravenous agents (e.g., propofol, remifentanil) and/or inhaled anesthetics, combined with muscle relaxants as needed.
PSA-LUNG scale score
Follow-up was conducted via in-hospital visits, remote contact and outpatient visits.
Time frame: Electronic questionnaires were administered at baseline (preoperatively), early postoperative period (day of surgery, POD 1, discharge day), and weekly within 4 weeks postoperatively. All assessments covered the entire perioperative period.
Pulmonary function test
Pulmonary function test
Time frame: 1 month after surgery
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — The study team has not yet decided whether to share individual participant data. The decision will depend on institutional policy, participant consent, and feasibility of data de-identification. This plan will be updated accordingly.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Affiliated Hospital of Guangzhou Medical University →